Office of Academic Resources
Chulalongkorn University
Chulalongkorn University

Home / Help

TitleRenal Cell Carcinoma [electronic resource] : Molecular Biology, Immunology, and Clinical Management / edited by Ronald M. Bukowski, Andrew C. Novick
ImprintTotowa, NJ : Humana Press : Imprint: Humana Press, 2000
Connect to
Descript XI, 434 p. online resource


Renal cell carcinoma represents a heterogeneous group of tumors, the most common of which is clear cell adenocarcinoma. The annual incidence of this tumor appears to be rising and approximately 12,000 individuals die from this cancer annually in the United States. One third of patients who present have metastatic disease at the time of diagnosis, and another 40% who undergo nephrectomy will ultimately develop this complication. Over the past 10 years, a significant amount of new information concerning the epidemiology, mole- lar and immunologic characteristics, and therapy for patients with these tumors has appeared. The recognition that inherited forms of renal cancer exist, and that chromosomal abn- malities can be identified in these tumors, suggested a genetic basis for renal cell carcinoma. The familial cancer syndrome, Von Hippel Lindau disease, provided the setting in which the genetic abnormalites associated with the development of renal cancer were first described. Abnormalities of the VHL gene have also been detected in sporadic clear cell carcinoma, and it has now been recognized that approximately 80 % of these tumors will demonstrate ch- acteristic alterations. Currently the functions of the VHL protein are being investigated, and the biology of clear cell carcinoma of the kidney is under study. Additionally, papillary carcinomas of the kidney appear to express different molecular defects, and these are now being unraveled


1 The Epidemiology of Renal Cell Carcinoma -- 2 The Pathology of Renal Neoplasms -- 3 Immunologic Response to Renal Cell Carcinoma -- 4 Molecular Mechanisms of Immune Dysfunction in Renal Cell Carcinoma -- 5 Molecular Genetics of Renal Cell Carcinoma -- 6 Screening for Renal Cell Carcinoma -- 7 Renal Cell Carcinoma: Diagnosis and Staging -- 8 Paraneoplastic Syndromes in Renal Cell Carcinoma -- 9 Prognostic Factors in Metastatic Renal Cell Carcinoma -- 10 Radical Nephrectomy and Nephron-Sparing Surgery for Localized Renal Cell Carcinoma -- 11 Management of Patients with Renal Cell Carcinoma and Vena Caval Thrombi -- 12 Laparoscopic Surgery for Renal Cell Carcinoma -- 13 Adjuvant Therapy for Renal Cell Carcinoma -- 14 The Role of Nephrectomy and Metastasectomy for Advanced Renal Cell Carcinoma -- 15 Management of Pulmonary Metastases in Renal Cell Carcinoma Patients -- 16 Management of Skeletal Metastases in Renal Cell Carcinoma Patients -- 17 Management of Central Nervous System Metastases in Renal Cell Carcinoma Patients -- 18 Chemotherapy for Metastatic Renal Cell Carcinoma (RCC) -- 19 Interleukin-2 in Metastatic Renal Cell Carcinoma -- 20 Role of Interferon in Metastatic Renal Cell Carcinoma -- 21 Combination Therapy for Treatment of Advanced Renal Cell Carcinoma -- 22 Monoclonal Antibodies in Advanced Renal Cell Carcinoma -- 23 Adoptive Immunotherapy in Renal Cell Carcinoma -- 24 Antiangiogenic Agents and Strategies in Renal Cell Carcinoma -- 25 Therapy for Patients with Uncommon Histologic Varieties of Renal Cell Carcinoma -- 26 Palliation in Patients with Advanced Renal Cell Carcinoma: The Interface with Antineoplastic Therapy

Medicine Oncology Medicine & Public Health Oncology


Office of Academic Resources, Chulalongkorn University, Phayathai Rd. Pathumwan Bangkok 10330 Thailand

Contact Us

Tel. 0-2218-2929,
0-2218-2927 (Library Service)
0-2218-2903 (Administrative Division)
Fax. 0-2215-3617, 0-2218-2907

Social Network


facebook   instragram